Month: March 2012

one of every two people whose parent is suffering from a heart disease family, will develop the disease -20 Years, the mortality of patients with hypertrophic cardiomyopathy (the most common hereditary heart) was up 6% annual; now, thanks to recent advances in diagnosis and treatment, including genetics, this mortality has fallen to 0.5 per cent per annum -genetic predisposition to suffer from cardiovascular disease, mainly cardiac insufficiencies, arrhythmias and sudden death, is present in one of every 250-300 children born alive and is transmitted from parents to children by up to 50% of cases – A more widespread use of genetics in cardiology will allow, as well as save resources in the follow-up of patients, develop more individualized treatments – in those families in which one of its members has been diagnosed with heart disease family, the Spanish Heart Foundation (CSF) recommends that their closest relatives refuse to submit to an assessment consistent clinic, at least, in a review of the clinical history and a realization of a physical examination, electrocardiogram and ultrasound Madrid, March 2012.- that genetics has been a very important advance in medicine in recent years is not something newThis has increasingly a more decisive role in the prevention, diagnosis and knowledge of cardiovascular disease, which it is. The Spanish Heart Foundation (CHF) wants to remind family heart diseases (diseases that have a high hereditary component)...

Almirall extends the rights of marketing of Sativex ® to Mexico. -Sativex ® is marketed by Almirall in various European countries -The medicinal product is in a second phase of approvals in Europe through a mutual recognition procedure – Sativex ® is currently in phase III for the treatment of cancer pain Barcelona, March 2012.- Almirall, S.A. ( Almirall ”) announces the signing with GW Pharma Ltd. ( GW ”) an update on their current agreement of Sativex ®. As part of the new agreement, Almirall has obtained the rights of marketing of Sativex ® in Mexico. Under the terms of the original license agreement signed in December 2005, Almirall gained exclusive rights to the marketing of Sativex ® in Europe (except United Kingdom). Almirall has now obtained the exclusive rights to market Sativex ® in Mexico, a country which has subsidiary for more than one decade. Luciano Conde, Director General operating from Almirall, said are very happy with our partnership with GW and the initial response of the market towards Sativex ®. It’s a new therapeutic option to alleviate suffering resulting from physical disability caused by muscle spasticity and Almirall is committed to ensure their availability in Europe, and now also in Mexico ”. Almirall recently launched Sativex ® as a drug prescription for spasticity in multiple sclerosis in Spain, Germany and Denmark. Future releases will 2012 be...

el Hospital Nisa Pardo de Aravaca promotes a Conference on the encephalomyelitis in Madrid chronic fatigue syndrome or miálgica -affects nine women for every man who suffers from. Spain between 0.1% and 1% of the population suffers from the syndrome of chronic fatigue (CFS) and up to 6% is troubled with fibromiálgia. – just 5% of people who suffer from this inflammation of the central nervous system and muscle recovers completely. Patients may see reduced its capacity to carry out the daily tasks between 50% and 80%. Madrid, March 2012. ­ – The control unit of encephalomyelitis miálgica and syndrome of chronic fatigue, Hospital Nisa Pardo de Aravaca under the supervision of the DRA. Garcia Quintana, has organized together with CUMED in the Complutense University of Madrid, the first annual Conference on miálgica in Madrid encephalomyelitis. At the meeting also helped Getafe University Hospital, the Hospital Puerta de Hierro, multidisciplinary group of the CFS of CMD of Barcelona, the Association of affected by CFS and the community of Madrid, LCN and Legal field laboratories SQM lawyers. According to said Manuel Vilches, managing director of Hospital Nisa Pardo de Aravaca, we are very excited with this day that we hope is the first step to create a unit specializing in the capital and also become the first of the successive annual Conference ”. Miálgica encephalomyelitis (Tomy), commonly known as chronic...